Drug intelligence / Profile preview

CF33-hNIS + pembrolizumab

Development stage: Unknown
Lead developer: Imugene
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intravenous, Intratumoral

Overview

CF33-hNIS + pembrolizumab is a combination investigational immunotherapy for advanced or metastatic solid tumors, including gastrointestinal cancers and cholangiocarcinoma. CF33-hNIS is a genetically engineered chimeric DNA vaccinia oncolytic virus armed with the human sodium-iodide symporter (hNIS) gene. It selectively infects and lyses tumor cells, releasing tumor and viral antigens to stimulate anti-tumor immune responses, with hNIS enabling imaging and potential radiotherapy strategies. Pembrolizumab is a humanized monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) on T cells, thereby enhancing T-cell-mediated anti-tumor immunity. This combination, investigated in phase 1 clinical trials, is designed to improve anti-tumor immune responses.

Brand names: Keytruda
Other names: human sodium-iodide symporter-armed CF33 chimeric vaccinia virus + pembrolizumab

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on CF33-hNIS + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CF33-hNIS + pembrolizumab.

Explore the full profile